Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance

R Alves, AC Gonçalves, S Rutella, AM Almeida… - Cancers, 2021 - mdpi.com
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Third-line therapy for chronic myeloid leukemia: current status and future directions

J Cortes, F Lang - Journal of Hematology & Oncology, 2021 - Springer
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Iron: The cancer connection

SV Torti, FM Torti - Molecular aspects of medicine, 2020 - Elsevier
Iron plays an essential role in normal biological processes: The generation of cellular
energy, oxygen transport, DNA synthesis and repair are all processes that require iron …

[HTML][HTML] Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells

M Carlsten, M Järås - Frontiers in immunology, 2019 - frontiersin.org
Natural killer (NK) cells are large granular lymphocytes involved in our defense against
certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti …

Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response

Y Ariav, JH Ch'ng, HR Christofk, N Ron-Harel… - Science advances, 2021 - science.org
Virus-infected cells and cancers share metabolic commonalities that stem from their
insatiable need to replicate while evading the host immune system. These similarities …

Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management

A Tefferi, T Barbui - American journal of hematology, 2020 - Wiley Online Library
Disease overview Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and …

The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder

R Roskoski Jr - Pharmacological research, 2020 - Elsevier
The human fibroblast growth factor family consists of 22 factors and five transmembrane
receptors. Of the 22 factors, eighteen are secreted while four of them function exclusively …

Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)

S Cirmi, A El Abd, L Letinier, M Navarra, F Salvo - Cancers, 2020 - mdpi.com
Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukemia
(CML), can be associated to cardiovascular (CV) adverse events (AEs). A case/non-case …

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

S Soverini, L Bavaro, C De Benedittis… - Blood, The Journal …, 2020 - ashpublications.org
In chronic myeloid leukemia (CML) patients, tyrosine kinase inhibitors (TKIs) may select for
drug-resistant BCR-ABL1 kinase domain (KD) mutants. Although Sanger sequencing (SS) is …

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

A Hochhaus, C Gambacorti-Passerini, C Abboud… - Leukemia, 2020 - nature.com
Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic
phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) …